{
  "symbol": "JNJ",
  "year": 2023,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.212,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.17
  },
  "top_positive": [
    {
      "sent": "Risks and uncertainties include, but are not limited to: Risks Related to Product Development, Market Success and Competition \u2022 Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company\u2019s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success; \u2022 Challenges to the Company\u2019s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets; \u2022 The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses; \u2022 Increasingly aggressive and frequent challenges to the Company\u2019s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected; \u2022 Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence; \u2022 Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies; \u2022 Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and \u2022 Allegations that the Company\u2019s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company\u2019s ability to sell the products in question and require the payment of money damages and future royalties.",
      "score": 0.9962
    },
    {
      "sent": "Risks Related to the Company\u2019s Strategic Initiatives, Healthcare Market Trends and the Planned Separation of the Company\u2019s Consumer Health Business \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures; \u2022 The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; \u2022 The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to rea\nTrends and the Planned Separation of the Company\u2019s Consumer Health Business \u2022 Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases; \u2022 Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; \u2022 Challenges to the Company\u2019s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures; \u2022 The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; \u2022 The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected; \u2022 The Company\u2019s ability to consummate the planned separation of the Company\u2019s Consumer Health business on a timely basis or at all; \u2022 The Company\u2019s ability to successfully separate the Company\u2019s Consumer Health business and realize the anticipated benefits from the planned separation; and \u2022 The New Consumer Health Company\u2019s ability to succeed as a standalone publicly traded company.",
      "score": 0.9874
    },
    {
      "sent": "Table of Content Part\u00a0I \u2014 FINANCIAL INFORMATION Item\u00a01 \u2014 FINANCIAL STATEMENTS JOHNSON & JOHNSON AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Unaudited; Dollars in Millions Except Share and Per Share Data) April 2, 2023 January 1, 2023 ASSETS Current assets: Cash and cash equivalents (Note 4) $ 19,170 14,127 Restricted cash (Note 4) 7,695 \u2014 Marketable securities 5,443 9,392 Accounts receivable, trade, less allowances $ 207 (2022, $ 203 ) 16,350 16,160 Inventories (Note 2) 12,809 12,483 Prepaid expenses and other 2,921 3,132 Total current assets 64,388 55,294 Property, plant and equipment at cost 50,367 49,253 Less: accumulated depreciation ( 30,193 ) ( 29,450 ) Property, plant and equipment, net 20,174 19,803 Intangible assets, net (Note 3) 47,448 48,325 Goodwill (Note 3) 45,575 45,231 Deferred taxes on income (Note 5) 8,817 9,123 Other assets 9,567 9,602 Total assets $ 195,969 187,378 LIABILITIES AND SHAREHOLDERS\u2019 EQUITY Current liabilities: Loans and notes payable $ 17,979 12,771 Accounts payable 9,909 11,703 Accrued liabilities 11,204 11,456 Accrued rebates, returns and promotions 14,784 14,417 Accrued compensation and employee related obligations 2,231 3,328 Accrued taxes on income (Note 5) 4,266 2,127 Total current liabilities 60,373 55,802 Long-term debt (Note 4) 34,928 26,888 Deferred taxes on income (Note 5) 4,417 6,374 Employee related obligations (Note 6) 6,665 6,767 Long-term taxes payable (Note 5) 4,296 4,306 Other liabilities 14,421 10,437 Total liabilities $ 125,100 110,574 Commitments and Contingencies (Note 11) Shareholders\u2019 equity: Common stock \u2014 par value $ 1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) $ 3,120 3,120 Accumulated other comprehensive income (loss) (Note 7) ( 12,626 ) ( 12,967 ) Retained earnings and Additional paid-in capital 124,558 128,345 Less: common stock held in treasury, at cost ( 521,519,000 and 506,246,000 shares) 44,183 41,694 Total shareholders\u2019 equity 70,869 76,804 Total liabilities and shareholders\u2019 equity $ 195,969 187,378 See Notes to Consolidated Financial Statements 1 Table of Content JOHNSON & JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited; Dollars & Shares in Millions Except Per Share Amounts) Fiscal First Quarter Ended April 2, 2023 Percent to Sales April 3, 2022 Percent to Sales Sales to customers (Note 9) $ 24,746 100.0 % $ 23,426 100.0 % Cost of products sold 8,395 33.9 7,598 32.4 Gross profit 16,351 66.1 15,828 67.6 Selling, marketing and administrative expenses 6,138 24.8 5,938 25.4 Research and development expense 3,563 14.4 3,462 14.8 In-process research and development 49 0.2 610 2.6 Interest income ( 235 ) ( 1.0 ) ( 22 ) ( 0.1 ) Interest expense, net of portion capitalized 215 0.9 10 0.0 Other (income) expense, net 7,228 29.2 ( 102 ) ( 0.4 ) Restructuri\non charge related to the talc settlement proposal.",
      "score": 0.9477
    }
  ],
  "top_negative": [
    {
      "sent": "Risks Related to Economic Conditions, Financial Markets and Operating Internationally \u2022 The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates; \u2022 The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins; \u2022 Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation; \u2022 The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems; \u2022 The impact of global public health crises and pandemics; \u2022 Changes to global climate, extreme weather and natural disasters that could affect demand for the Company\u2019s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company\u2019s products and operations; and \u2022 The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.",
      "score": -0.891
    },
    {
      "sent": "Risks Related to Supply Chain and Operations \u2022 Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action; \u2022 Interruptions and breaches of the Company\u2019s information technology systems or those of the Company\u2019s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; \u2022 Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company\u2019s products; and \u2022 The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities.",
      "score": -0.765
    },
    {
      "sent": "For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued.",
      "score": -0.765
    }
  ],
  "forward_snippets": [
    "On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies.",
    "The growth was driven by price actions, one-time supply replenishment and sun season pipeline fill, and e-commerce and club channel performance driven by new product innovations in NEUTROGENA and AVEENO."
  ]
}